现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • CB-1158 Hydrochloride (INCB01158 Hydrochloride)
CB-1158 Hydrochloride (INCB01158 Hydrochloride)的可视化放大

CB-1158 Hydrochloride (INCB01158 Hydrochloride)

An arginase inhibitor

原价
¥2587-8762
价格
2070-7010
CB-1158 Hydrochloride (INCB01158 Hydrochloride)的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajcx13444
  • CAS: N/A
  • 别名:
  • 分子式: C11H24BCl2N3O5
  • 分子量: 360.04
  • 纯度: >98%
  • 溶解度: Water : ≥ 50 mg/mL (138.87 mM);DMSO : < 1 mg/mL (insoluble or slightly soluble)
  • 储存: Store at -20°C
  • 库存: 现货

Background

CB-1158 is an inhibitor of arginase I and II (IC50s = 0.086 and 0.296 ?M for the human enzymes, respectively).1 It is selective for arginase I and II over neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS; IC50s = >50 ?M for all). CB-1158 reverses inhibition of T cell proliferation induced by granulocytes in vitro (IC50 = 0.204 ?M). It reduces tumor growth in a CT26 murine colon cancer model when administered at a dose of 100 mg/kg twice per day.


1.Steggerda, S.M., Bennett, M.K., Chen, J., et al.Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironmentJ. Immunother. Cancer5(1)101(2017)

Protocol

Cell experiment:

Intracellular arginase activity is determined for the arginase-expressing HepG2 and K-562 cell lines as follows. HepG2 cells are seeded at 100,000 cells per well one day prior to treatment with CB-1158. K-562 cells are seeded at 200,000 cells per well on the day of CB-1158 treatment. Cells are treated with a dose-titration of CB-1158 in SILAC RPMI-1640 media containing 5% heat-inactivated and dialyzed FBS, antibiotics/anti-mycotic, 10 mM L-arginine, 0.27 mM L-lysine, and 2 mM L-glutamine. The medium is harvested after 24 h and urea generated is determined. Wells containing media without cells are used as background controls. For assessing the effect of CB-1158 on Arg1 in primary hepatocytes, frozen human hepatocytes are thawed, allowed to adhere onto collagen-coated wells for 4 h, and then incubated for 48 h in SILAC-RPMI containing 10 mM L-ornithine, no L-arginine, and a dose-titration of CB-1158, at which time the media are analyzed for urea[1].

Animal experiment:

Mice[1]For the 4T1 tumor model, 105 cells are injected orthotopically into the mammary fat pad; for all other tumor models, 106 cells are injected subcutaneously (s.c.) in the right flank. For all studies, CB-1158 is administered by oral gavage twice per day at 100 mg/kg starting on study day 1 (1 day after tumor implant). Control groups receive vehicle (water) twice daily by gavage. Tumor volume measured by digital caliper (length?×?width?×?width/2) and body weight are recorded three times per week. Mice are euthanized when tumors necrotize or volumes reach 2000 mm3. For the CT26 model, anti-PD-L1 antibody (5 mg/kg) is injected intraperitoneally (i.p.) on days 5, 7, 9, 11, 13, and 15. For the 4T1 model, anti-CTLA-4 antibody (5 mg/kg) is injected i.p. on days 2, 5, and 8; anti-PD-1 antibody (5 mg/kg) is injected i.p. on days 3, 6, and 9. 4T1 tumors are harvested on study day 25 into Fekete’s solution and tumor nodules are enumerated visually. Gemcitabine is dosed 50 mg/kg i.p. on days 10 and 16 for the CT26 model, 60 mg/kg i.p. on days 6 and 10 for the LLC model, or 30 mg/kg i.p. on day 5 for the 4T1 model. With these regimens, gemcitabine modestly reduces tumor growth and spares most tumor-infiltrating immune cells, allowing for the evaluation of combination activity with CB-1158[1].

参考文献:

[1]. Steggerda SM, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017 Dec 19;5(1):101.

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服